

BUMRUNGRAD HOSPITAL

THAILAND / HEALTH CARE SERVICES

BH TB

HOLD

UNCHANGED

แนวโน้ม 3Q25 เป็นบวก

- การฟื้นตัวของปริมาณคนไข้ชาวต่างประเทศ และปัจจัยฤดูกาลหนุนการดำเนินงาน 2H25 และแนวโน้มกำไร 3Q25 ที่คาดว่าจะแข็งแกร่ง
- ปรับเพิ่มประมาณการกำไรปกติปี 2025 แต่คาดว่าจะยังคงลดลง 5% y-y ก่อนจะกลับมาเติบโตราว 4% ในปี 2026-27
- ปรับเพิ่มราคาเป้าหมายเป็น 193 บาท คงคำแนะนำถือ

TARGET PRICE	THB193.00
CLOSE	THB178.50
UP/DOWNSIDE	+8.1%
PRIOR TP	THB160.00
CHANGE IN TP	+20.6%
TP vs CONSENSUS	+3.1%

KEY STOCK DATA

YE Mar (THB m)	2024	2025E	2026E	2027E
Revenue	25,718	25,197	26,212	27,803
Net profit	7,775	7,422	7,692	7,976
EPS (THB)	9.77	9.33	9.67	10.02
vs Consensus (%)	-	4.4	5.9	6.3
EBITDA	10,265	10,079	10,483	11,011
Recurring net profit	7,798	7,422	7,692	7,976
Core EPS (THB)	9.80	9.33	9.67	10.02
Chg. In EPS est. (%)	-	4.7	5.3	5.4
EPS growth (%)	12.7	(4.8)	3.6	3.7
Core P/E (x)	18.2	19.1	18.5	17.8
Dividend yield (%)	2.9	2.8	3.1	3.2
EV/EBITDA (x)	12.7	12.6	11.9	11.0
Price/book (x)	5.2	4.6	4.2	3.8
Net debt/Equity (%)	(43.1)	(47.9)	(52.8)	(56.6)
ROE (%)	30.4	25.4	23.6	22.2

คาดหวังปริมาณคนไข้ต่างชาติกลับมา

BH ประเมินแนวโน้มการดำเนินงานในช่วง 2H25 จะดีขึ้นเมื่อเทียบกับในช่วง 1H25 จาก Revenue intensity โดยมีปัจจัยหนุนสำคัญ: 1) รายได้คนไข้ชาวตะวันออกกลาง (โอมาน กатар สหรัฐอาหรับเอมิเรตส์) หดตัวในอัตราที่น้อยลง y-y หลังปริมาณผู้ป่วยนอกและผู้ป่วยในปรับตัวดีขึ้นมาตั้งแต่เดือน มิ.ย.; 2) รายได้คนไข้ชาวคูเวตที่ลดลงจากการชะลอส่งตัวเข้ามารักษาในได้ปรับฐานไปเรียบร้อยแล้ว; และ 3) รายได้คนไข้กลุ่มประเทศอินโดจีนฟื้นตัว บนความคาดหวังต่อสถานการณ์ความไม่สงบทางภูมิรัฐศาสตร์ที่ผ่อนคลาย อย่างไรก็ตาม ยังไม่มีความชัดเจนเกี่ยวกับช่วงเวลาที่จะกลับมาส่งต่อผู้ป่วยที่รัฐบาลรับประกันการชำระเงิน เข้ามารักษาในไทย ซึ่งยังเป็นประเด็นคงค้างต่อไป

แนวโน้มกำไร 3Q25 แข็งแกร่ง


ผู้บริหารคาดว่าจะรายได้เติบโต 3-5% y-y ใน 3Q25 ซึ่งเป็น High season และเชื่อมั่นประสิทธิภาพการบริหารต้นทุนโรงพยาบาลอย่างต่อเนื่อง หลังบริษัทมี EBITDA margin ทำสถิติใหม่ใน 2Q25 เมื่อต้นไตรมาสกำไรปกติ 3Q25 จะทำสถิติสูงสุดใหม่ที่ 2.05 พัน ลบ. (+10% q-q, +3% y-y) บนสมมติฐานรายได้ 6.6 พัน ลบ. (+10% q-q, +3% y-y) และ EBITDA margin ที่ 41% (ทรงตัว q-q และ y-y) อย่างไรก็ตาม เรายังคงคาดว่าผลประกอบการ 4Q25 จะอ่อนตัวตามปัจจัยฤดูกาล

ปรับเพิ่มประมาณการ แต่ยังคาดว่าจะกำไรปี 2025 ลดลง 5%

เราปรับเพิ่มประมาณการกำไรปกติปี 2025-27 ขึ้น 5% ต่อปี เพื่อสะท้อนผลประกอบการ 2Q25 ที่ดี และคาดการณ์ 3Q25 เติบโต ทั้งนี้ เราปรับประมาณการรายได้ขึ้น 2% และ EBITDA margin ขึ้น 1-1.2ppt เป็น 40% ปัจจัยหนุนจากแนวโน้มคนไข้ชาวต่างชาติที่คาดว่าจะดีขึ้น เราจึงประเมินกำไรปกติปี 2025 ลดลง 5% y-y เป็น 7.4 พัน ลบ. ก่อนเพิ่มขึ้นราว 4% ในปี 2026-27 คาดการเติบโตของรายได้เร่งตัวขึ้นเป็น 6% ในปี 2027 (2026E: +4%) ภายหลังโรงพยาบาลใหม่ในภูเก็ตเปิดให้บริการใน 1Q27 แม้ยังเผชิญต้นทุนสูงในช่วง 2-3 ปีแรกของการดำเนินงาน

ปรับเพิ่มราคาเป้าหมาย คงคำแนะนำถือ

เราปรับเพิ่มราคาเป้าหมายเป็น 193 จาก 160 บาท (DCF, 8.2% WACC, 3% terminal growth) เทียบเท่า 20x 2026E P/E หรือราว -0.5SD ของค่าเฉลี่ยการซื้อขายหุ้นย้อนหลัง 5 ปี ซึ่งสอดคล้องกับ Targeted valuations (-0.5SD) ของหุ้นโรงพยาบาลขนาดใหญ่ที่เราทำการศึกษา ทั้งนี้เราปรับเพิ่ม Implied P/E จาก 16x เป็น 20x จากการปรับลดสมมติฐานค่า Beta ลงเป็น 0.7 (จาก 0.8) สะท้อนแนวโน้มความผันผวนของผลประกอบการที่ลดลง ราคาหุ้น BH ที่ปรับตัวขึ้นเมื่อเร็ว ๆ นี้ มาจากปัจจัยบวกระยะสั้น (ผลประกอบการ 2Q25 แข็งแกร่ง การกลับมาของคนไข้ชาวตะวันออกกลาง และแนวโน้มกำไรที่ดีขึ้น 3Q25) ส่งผลให้มี Upside จำกัด ขณะที่แรงกดดันจากการแข่งขันยังคงอยู่



Share price performance	1 Month	3 Month	12 Month
Absolute (%)	28.9	7.5	(27.7)
Relative to country (%)	17.4	4.9	(22.8)
Mkt cap (USD m)			4,372
3m avg. daily turnover (USD m)			19.5
Free float (%)			72
Major shareholder	Bangkok Insurance (11%)		
12m high/low (THB)			284.00/130.00
Issued shares (m)			922.70

Sources: Bloomberg consensus; FSSIA estimates





Vatcharut Vacharawongsith

Fundamental Investment Analyst on Securities; License no. 018301
vatcharut.v@fssia.com, +66 2646 9969

PREPARED BY FSS INTERNATIONAL INVESTMENT ADVISORY SECURITIES CO LTD (FSSIA). ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES CAN BE FOUND AT THE END OF THIS REPORT

บทวิเคราะห์ฉบับนี้แปลมาจากต้นฉบับภาษาอังกฤษ ที่ออกรายงานเมื่อวันที่ 5 สิงหาคม 2025

<div><h3>Investment thesis</h3><p>BH's core operations are experiencing pressure from soft fly-in patient volumes, economic slowdown, and rising competition, which may undermine its patient volume this year. International patient revenue should improve from 2026 onwards on the back of normalized strong demand for medical tourism.</p><p>BH's EBITDA margin may be fluctuate over the next three years. The new hospital ramp-up in Phuket may cap the profit margin recovery in 2027. We expect mild earnings growth of 3-4% in 2026-27, but still below 2024 levels.</p><p>ROE and margins remain above peers but are trending lower. Expansion into new source markets offers upside, but materialized earnings impact may persist in the longer term.</p><h3>Company profile</h3><p>BH is a leading private hospital (580 licensed beds) in the premium segment.</p><p>www.bumrungrad.com</p></div>	<div><h3>Principal activities (revenue, 2024)</h3><div><div><div>■ Thai patient revenue - 33.9 %</div><div>■ International patient revenue - 65.8 %</div><div>■ Other revenue - 0.3 %</div></div></div><div>Source: Bumrungrad Hospital</div></div> <div><h3>Major shareholders</h3><div><div><div>■ Bangkok Insurance - 11.0 %</div><div>■ Thai NVDR - 10.4 %</div><div>■ UOB Kay Hian (Hong Kong) - 7.8 %</div><div>■ Bangkok Bank - 6.7 %</div><div>■ Others - 64.2 %</div></div></div><div>Source: Bumrungrad Hospital</div></div>
--	--

Catalysts

Key growth drivers include 1) a new market including patients from Saudi Arabia and China; 2) the new hospital in Phuket, which will unlock growth from the standalone model; and 3) the vital life business (Wellness), which has a high margin compared to traditional healthcare.

Risks to our call

Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests or floods; 2) regulatory risks from drug prices and medical bill controls; and 3) higher medical fee discount promotions, leading to a weaker EBITDA margin.

Event calendar

Date	Event
Nov 2025	3Q25 results announcement

Key assumptions

	2025E	2026E	2027E
	(%)	(%)	(%)
OPD Volume growth	(3)	2	3
OPD revenue / patient growth	1	2	3
IPD Volume growth	(3)	2	3
IPD revenue / patient growth	1	2	3


Source: FSSIA estimates

Earnings sensitivity

- For every 1% increase in patient volume, we project 2025 earnings to rise by 2%, and vice versa, all else being equal.
- For every 1% increase in EBITDA margin, we project 2025 earnings to rise by 4%, and vice versa, all else being equal.


Source: FSSIA estimates

Exhibit 1: Patient revenue growth by nationality in 1Q25




Source: BH

Exhibit 2: Patient revenue growth by nationality in 2Q25




Source: BH

Exhibit 3: Non-Thai patient revenue growth in 1Q25



Source: BH

Exhibit 4: Non-Thai patient revenue growth in 2Q25



Source: BH

Exhibit 5: International revenue by top nationalities in 1Q25

Net Patient Revenues - %Variance	
Nationality	1Q2025 vs 1Q2024
1 Qatar	-24.4%
2 Myanmar	19.8%
3 United States	17.1%
4 Cambodia	-7.1%
5 Bangladesh	-16.8%
6 United Arab Emirates	-39.6%
7 Mongolia	-10.2%
8 China	-11.6%
9 Ethiopia	-3.6%
10 Oman	-33.6%
Total International	-11.6%


Source: BH

Exhibit 6: International revenue by top nationalities in 2Q25

Net Patient Revenues - % Variance YoY		
Nationality	2Q2025 vs 2Q2024	1H2025 vs 1H2024
1 Qatar	-13.3%	-19.3%
2 Myanmar	+10.1%	+15.3%
3 United States	+6.9%	+13.9%
4 Bangladesh	+5.8%	-5.8%
5 Cambodia	-28.5%	-17.8%
6 United Arab Emirates	-1.0%	-21.4%
7 China	-21.7%	-12.9%
8 United Kingdom	+3.4%	+6.2%
9 Mongolia	-10.3%	-9.7%
10 Oman	-13.4%	-23.7%
Total Non-Thai Patients	-6.6%	-8.2%


Source: BH

Exhibit 7: International patient revenue



Sources: BH; FSSIA estimates

Exhibit 8: Thai patient revenue



Sources: BH; FSSIA estimates

Exhibit 9: BH – 3Q25E results preview

	3Q24	4Q24	1Q25	2Q25	3Q25E	Change		2025E	Change
	(THB m)	(THB m)	(THB m)	(THB m)	(THB m)	(q-q %)	(y-y %)	(THB m)	(y-y %)
Sales	6,405	6,473	6,141	6,024	6,597	10	3	25,197	(2)
COGS (incl. depreciation)	(3,089)	(3,259)	(3,040)	(2,864)	(3,136)	10	2	(12,281)	(2)
Gross Profit	3,316	3,214	3,101	3,160	3,461	10	4	12,916	(2)
SG&A	(1,003)	(1,142)	(1,084)	(961)	(1,053)	10	5	(4,213)	1
Operating Profit	2,313	2,072	2,017	2,199	2,408	10	4	8,703	(4)
Net other income	41	46	67	77	78	2	89	290	100
Interest income	74	66	63	52	61	15	(18)	242	(13)
Interest expense	(2)	(2)	(2)	(2)	(2)	(10)	(6)	(8)	
Pretax profit	2,426	2,182	2,146	2,326	2,545	9	5	9,227	(2)
Income Tax	(424)	(279)	(400)	(449)	(484)	8	14	(1,744)	9
Share gain/loss from JV	(0)	(0)	(0)	(0)	0				
Share gain/loss from associates	(0)	(0)	0	(0)	(1)			(0)	5
Minority interest	(12)	(7)	(10)	(22)	(15)			(61)	6
Core profit	1,990	1,896	1,736	1,855	2,045	10	3	7,422	(5)
Extraordinaries, GW & FX	(34)	7	(2)	3	(0)			0	
Reported net profit	1,955	1,903	1,734	1,858	2,045	10	5	7,422	(5)
Outstanding shares (m)	796	796	796	796	796	0	0	796	0
Core EPS (THB)	2.50	2.38	2.18	2.33	2.57	10	3	9.33	(5)
EPS (THB)	2.46	2.39	2.18	2.33	2.57	10	5	9.33	(5)
COGS (excl. depreciation)	2,820	2,984	2,784	2,605	2,876	10	2	11,195	(2)
Depreciation	269	275	256	259	261	1	(3)	1,086	1
EBITDA	2,623	2,393	2,340	2,534	2,747	8	5	10,079	(2)
Key ratios	(%)	(%)	(%)	(%)	(%)	(ppt)	(ppt)	(%)	(ppt)
Gross margin	52	50	50	52	52	0	1	51	(0)
SG&A/Revenue	16	18	18	16	16	0	0	17	1
EBITDA margin	41	37	38	42	41	(0)	0	40	0
Net profit margin	31	29	28	31	31	0	0	29	(1)

Sources: BH; FSSIA estimates

Exhibit 10: Earnings revisions

	Current			Previous			Change (%)		
	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E
OPD patient revenue (THB b)	12.6	13.1	13.9	12.3	12.8	13.6	2.1	2.1	1.9
IPD patient revenue (THB b)	12.6	13.1	13.9	12.3	12.8	13.6	2.1	2.1	1.9
Thai patient revenue (THB b)	8.8	9.1	9.3	8.8	9.1	9.3	0.0	0.0	0.0
International patient revenue (THB b)	16.3	17.1	18.4	15.8	16.5	17.8	3.2	3.4	3.3
Revenue (THB b)	25.2	26.2	27.8	24.7	25.7	27.2	2.0	2.0	2.2
EBITDA Margin (%)	40.0	40.0	39.6	38.8	39.0	38.6	1.2	1.0	1.0
Core profit (THB b)	7.4	7.7	8.0	7.1	7.3	7.6	4.5	5.4	5.0

Source: FSSIA estimates


Exhibit 11: DCF valuation

Cost of equity assumptions	(%)	Cost of debt assumptions	(%)
Risk-free rate	3.0	Pre-tax cost of debt	3.5
Market risk premium	8.5	Marginal tax rate	20.0
Stock beta	0.7		
Cost of equity, Ke	8.8	Net cost of debt, Kd	2.8
Weight applied	90.0	Weight applied	10.0
WACC	8.2		

DCF valuation estimate	(THB m)	(THB/share)	Comments
NPV	59,091	64.0	WACC 8.2%, Risk free rate 3%, Risk premium 8.5%
Terminal value	101,115	109.6	Terminal growth 3%
Cash & liquid assets	18,397	19.9	
Investments	130	0.1	
Debt	(139)	(0.2)	
Minorities	(438)	(0.5)	
Residual ordinary equity	178,155.6	193	


Source: FSSIA estimates

Exhibit 12: One-year forward rolling P/E band



Sources: Bloomberg; FSSIA estimates

Exhibit 13: One-year forward rolling P/BV band



Sources: Bloomberg; FSSIA estimates

Financial Statements

Bumrungrad Hospital

Profit and Loss (THB m) Year Ending Mar	2023	2024	2025E	2026E	2027E
Revenue	25,376	25,718	25,197	26,212	27,803
Cost of goods sold	(12,895)	(12,503)	(12,281)	(12,773)	(13,688)
Gross profit	12,481	13,215	12,916	13,439	14,116
Other operating income	111	145	290	246	254
Operating costs	(4,180)	(4,171)	(4,213)	(4,356)	(4,676)
Operating EBITDA	9,509	10,265	10,079	10,483	11,011
Depreciation	(1,097)	(1,077)	(1,086)	(1,153)	(1,319)
Goodwill amortisation	-	-	-	-	-
Operating EBIT	8,412	9,188	8,993	9,329	9,693
Net financing costs	139	271	234	235	301
Associates	(1)	0	0	0	0
Recurring non-operating income	(1)	0	0	0	0
Non-recurring items	88	(23)	0	0	0
Profit before tax	8,638	9,436	9,227	9,564	9,994
Tax	(1,583)	(1,604)	(1,744)	(1,808)	(1,949)
Profit after tax	7,055	7,832	7,483	7,757	8,045
Minority interests	(49)	(57)	(61)	(64)	(68)
Preferred dividends	-	-	-	-	-
Other items	-	-	-	-	-
Reported net profit	7,006	7,775	7,422	7,692	7,976
Non-recurring items & goodwill (net)	(88)	23	0	0	0
Recurring net profit	6,918	7,798	7,422	7,692	7,976
Per share (THB)					
Recurring EPS *	8.69	9.80	9.33	9.67	10.02
Reported EPS	8.80	9.77	9.33	9.67	10.02
DPS	3.69	5.15	5.00	5.60	5.80
Diluted shares (used to calculate per share data)	796	796	796	796	796
Growth					
Revenue (%)	22.5	1.3	(2.0)	4.0	6.1
Operating EBITDA (%)	33.4	8.0	(1.8)	4.0	5.0
Operating EBIT (%)	40.0	9.2	(2.1)	3.7	3.9
Recurring EPS (%)	40.0	12.7	(4.8)	3.6	3.7
Reported EPS (%)	41.9	11.0	(4.5)	3.6	3.7
Operating performance					
Gross margin inc. depreciation (%)	49.2	51.4	51.3	51.3	50.8
Gross margin exc. depreciation (%)	53.5	55.6	55.6	55.7	55.5
Operating EBITDA margin (%)	37.5	39.9	40.0	40.0	39.6
Operating EBIT margin (%)	33.1	35.7	35.7	35.6	34.9
Net margin (%)	27.3	30.3	29.5	29.3	28.7
Effective tax rate (%)	18.5	17.0	18.9	18.9	19.5
Dividend payout on recurring profit (%)	42.5	52.6	53.6	57.9	57.9
Interest cover (X)	(60.7)	(33.9)	(38.4)	(39.6)	(32.2)
Inventory days	10.6	11.5	11.5	11.2	11.0
Debtor days	50.8	59.5	57.7	55.5	52.3
Creditor days	33.5	35.6	37.1	36.0	35.6
Operating ROIC (%)	52.9	54.7	50.6	51.6	52.9
ROIC (%)	51.0	49.1	42.9	43.8	45.0
ROE (%)	31.8	30.4	25.4	23.6	22.2
ROA (%)	25.6	24.7	21.2	20.0	18.9
* Pre-exceptional, pre-goodwill and fully diluted					
Revenue by Division (THB m)					
Thai patient revenue	8,348	8,716	8,803	9,067	9,339
International patient revenue	16,948	16,919	16,311	17,062	18,381
Other revenue	80	83	83	83	83

Sources: Bumrungrad Hospital; FSSIA estimates

Financial Statements

Bumrungrad Hospital

Cash Flow (THB m) Year Ending Mar	2023	2024	2025E	2026E	2027E
Recurring net profit	6,918	7,798	7,422	7,692	7,976
Depreciation	1,097	1,077	1,086	1,153	1,319
Associates & minorities	-	-	-	-	-
Other non-cash items	(16)	(1,846)	61	64	68
Change in working capital	(1,021)	(56)	(64)	123	198
Cash flow from operations	6,978	6,973	8,506	9,033	9,561
Capex - maintenance	(1,617)	(1,380)	(1,512)	(1,311)	(1,668)
Capex - new investment	-	-	-	-	-
Net acquisitions & disposals	(12)	(117)	0	0	0
Other investments (net)	-	-	-	-	-
Cash flow from investing	(1,629)	(1,497)	(1,512)	(1,311)	(1,668)
Dividends paid	(2,938)	(4,101)	(3,979)	(4,453)	(4,615)
Equity finance	0	0	0	0	0
Debt finance	28	48	0	0	0
Other financing cash flows	31	(55)	0	0	0
Cash flow from financing	(2,880)	(4,108)	(3,979)	(4,453)	(4,615)
Non-recurring cash flows	-	-	-	-	-
Other adjustments	0	0	0	0	0
Net other adjustments	0	0	0	0	0
Movement in cash	2,469	1,368	3,015	3,269	3,278
Free cash flow to firm (FCFF)	5,351.60	5,484.09	7,002.04	7,789.43	7,960.45
Free cash flow to equity (FCFE)	5,407.78	5,469.17	6,993.67	7,722.27	7,893.29

Per share (THB)

FCFF per share	5.80	5.94	7.59	8.44	8.63
FCFE per share	5.86	5.93	7.58	8.37	8.55
Recurring cash flow per share	10.05	8.83	10.77	11.20	11.77

Balance Sheet (THB m) Year Ending Mar	2023	2024	2025E	2026E	2027E
Tangible fixed assets (gross)	27,899	28,832	30,343	31,654	33,322
Less: Accumulated depreciation	(14,921)	(15,503)	(16,590)	(17,743)	(19,062)
Tangible fixed assets (net)	12,978	13,328	13,754	13,911	14,260
Intangible fixed assets (net)	61	60	60	60	60
Long-term financial assets	-	-	-	-	-
Invest. in associates & subsidiaries	13	130	130	130	130
Cash & equivalents	10,745	12,113	15,128	18,397	21,675
A/C receivable	4,408	3,982	3,982	3,982	3,982
Inventories	362	356	349	362	385
Other current assets	169	280	274	285	303
Current assets	15,685	16,732	19,734	23,027	26,345
Other assets	475	2,403	2,403	2,403	2,403
Total assets	29,212	32,653	36,081	39,531	43,199
Common equity	23,801	27,488	30,931	34,170	37,531
Minorities etc.	297	313	374	438	507
Total shareholders' equity	24,098	27,801	31,305	34,609	38,038
Long term debt	91	139	139	139	139
Other long-term liabilities	856	923	923	923	923
Long-term liabilities	947	1,062	1,062	1,062	1,062
A/C payable	1,078	1,149	1,126	1,168	1,244
Short term debt	0	0	0	0	0
Other current liabilities	3,089	2,641	2,587	2,692	2,855
Current liabilities	4,167	3,790	3,713	3,860	4,099
Total liabilities and shareholders' equity	29,212	32,653	36,081	39,531	43,199
Net working capital	772	828	892	770	572
Invested capital	14,299	16,750	17,239	17,274	17,425

* Includes convertibles and preferred stock which is being treated as debt

Per share (THB)

Book value per share	29.91	34.54	38.87	42.94	47.16
Tangible book value per share	29.83	34.47	38.79	42.86	47.09

Financial strength

Net debt/equity (%)	(44.2)	(43.1)	(47.9)	(52.8)	(56.6)
Net debt/total assets (%)	(36.5)	(36.7)	(41.5)	(46.2)	(49.9)
Current ratio (x)	3.8	4.4	5.3	6.0	6.4
CF interest cover (x)	(38.0)	(19.2)	(28.9)	(31.8)	(25.2)

Valuation	2023	2024	2025E	2026E	2027E
Recurring P/E (x) *	20.5	18.2	19.1	18.5	17.8
Recurring P/E @ target price (x) *	22.2	19.7	20.7	20.0	19.3
Reported P/E (x)	20.3	18.3	19.1	18.5	17.8
Dividend yield (%)	2.1	2.9	2.8	3.1	3.2
Price/book (x)	6.0	5.2	4.6	4.2	3.8
Price/tangible book (x)	6.0	5.2	4.6	4.2	3.8
EV/EBITDA (x) **	13.8	12.7	12.6	11.9	11.0
EV/EBITDA @ target price (x) **	15.1	13.8	13.8	13.0	12.0
EV/invested capital (x)	9.2	7.8	7.4	7.2	6.9

* Pre-exceptional, pre-goodwill and fully diluted ** EBITDA includes associate income and recurring non-operating income

Sources: Bumrungrad Hospital; FSSIA estimates

Bumrungrad Hospital PCL (BH TB)

FSSIA ESG rating


51.21 /100

Exhibit 14: FSSIA ESG score implication

Rating	Score	Implication
★★★★★	>79-100	Leading its industry peers in managing the most significant ESG risks which not only better cost efficiency but also lead to higher profitability.
★★★★★	>59-79	A mixed track record of managing the most significant ESG risks and opportunities relative to industry peers.
★★★	>39-59	Relevant ESG materiality matrix has been constructively addressed, well-managed and incorporated into day-to-day operations, in which targets and achievements are evaluated annually.
★★	>19-39	Relevant ESG materiality matrix has been identified with key management in charge for progress to be followed up on and to provide intensive disclosure. Most targets are conventional and achievable.
★	1-19	The company has adopted the United Nations Sustainable Development Goals (UN SDGs), established sustainability management guidelines and fully complies with regulations or ESG suggested guidance from related organizations such as the SET and SEC.

Sources: FSSIA estimates

Exhibit 15: ESG – peer comparison

	FSSIA ESG score	Domestic ratings						Global ratings					Bloomberg		
		DJSI	SET ESG	ESG Rating	CG score	AGM level	Thai CAC	Morningstar ESG risk	ESG Book	MSCI	Moody's	Refinitiv	S&P Global	ESG score	Disclosure score
SET100	69.20	5.34	4.40	4.40	4.76	4.65	3.84	Medium	51.76	BBB	20.87	58.72	63.91	3.72	28.17
Coverage	67.12	5.11	4.15	4.17	4.83	4.71	3.53	Medium	52.04	BB	16.97	56.85	62.09	3.40	31.94
BCH	39.71	--	--	--	4.00	5.00	Certified	High	48.21	--	--	27.19	18.00	3.52	47.60
BDMS	74.00	Y	Y	Y	5.00	4.00	--	Medium	61.06	AA	34.00	59.83	72.00	3.45	58.92
BH	51.21	--	--	--	4.00	4.00	--	Medium	64.29	A	29.00	59.03	27.00	5.08	47.79
CHG	38.25	--	--	--	4.00	5.00	--	High	55.35	--	--	59.57	21.00	2.34	50.24
PR9	54.08	--	Y	Y	5.00	5.00	Certified	High	71.12	--	--	62.39	--	2.43	37.90
PRINC	18.00	--	--	--	4.00	4.00	Certified	--	--	--	--	--	--	--	--
RAM	11.75	--	--	--	3.00	--	--	High	--	--	--	--	--	--	--
THG	18.75	--	--	--	5.00	5.00	--	High	--	--	--	--	--	--	--
VIBHA	20.88	--	--	--	4.00	3.00	Declared	High	--	--	--	--	17.00	--	--

Sources: [SETTRADE.com](https://www.settrade.com); FSSIA's compilation

Exhibit 16: ESG score by Bloomberg

FY ending Dec 31	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022
ESG financial materiality scores - ESG score	0.85	1.30	1.60	1.49	1.73	3.35	3.58	5.08
BESG environmental pillar score	0.00	1.75	1.75	1.75	1.75	3.21	3.73	3.73
BESG social pillar score	0.18	0.18	0.38	0.38	0.85	3.19	3.25	6.43
BESG governance pillar score	3.25	3.57	4.35	3.81	3.55	3.73	4.07	3.97
ESG disclosure score	31.24	32.94	35.78	35.78	36.40	47.68	47.79	47.79
Environmental disclosure score	0.42	5.53	8.91	8.91	9.76	35.43	35.76	35.76
Social disclosure score	12.03	12.03	17.17	17.17	18.20	26.39	26.39	26.39
Governance disclosure score	81.10	81.10	81.10	81.10	81.10	81.10	81.10	81.10
Environmental								
Emissions reduction initiatives	No	No	No	No	No	Yes	Yes	Yes
Climate change policy	No	No	No	No	No	Yes	Yes	Yes
Climate change opportunities discussed	No	No	No	No	No	No	No	No
Risks of climate change discussed	No	No	No	No	No	No	Yes	Yes
GHG scope 1	—	—	—	—	—	—	—	—
GHG scope 2 location-based	—	—	—	—	—	—	—	—
GHG Scope 3	—	—	—	—	—	—	—	—
Carbon per unit of production	—	—	—	—	—	—	—	—
Biodiversity policy	No	No	No	No	No	No	No	No
Energy efficiency policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Total energy consumption	—	0	0	0	0	0	0	0
Renewable energy use	—	—	—	—	—	—	—	—
Electricity used	—	—	—	—	—	—	—	—
Fuel used - natural gas	—	—	—	—	—	—	—	—

Sources: Bloomberg; FSSIA's compilation

Exhibit 17: ESG score by Bloomberg (cont.)

FY ending Dec 31	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022
Fuel used - crude oil/diesel	No	No	No	No	No	No	No	No
Waste reduction policy	No	No	No	No	No	Yes	Yes	Yes
Hazardous waste	—	—	—	—	—	—	—	—
Total waste	—	—	—	—	—	—	—	—
Waste recycled	—	—	—	—	—	—	—	—
Waste sent to landfills	—	—	—	—	—	—	—	—
Environmental supply chain management	No	No	No	No	No	Yes	Yes	Yes
Water policy	No	No	No	No	Yes	Yes	Yes	Yes
Water consumption	—	—	—	—	—	—	—	—
Social								
Human rights policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Policy against child labor	No	No	No	No	Yes	Yes	Yes	Yes
Quality assurance and recall policy	No	No	No	No	No	Yes	Yes	Yes
Consumer data protection policy	No	No	No	No	No	Yes	Yes	Yes
Equal opportunity policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Gender pay gap breakout	No	No	No	No	No	No	No	No
Pct women in workforce	—	—	—	—	—	—	—	—
Pct disabled in workforce	—	—	—	—	—	—	—	—
Business ethics policy	No	No	No	No	No	Yes	Yes	Yes
Anti-bribery ethics policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Health and safety policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Lost time incident rate - employees	—	—	—	—	—	—	—	—
Total recordable incident rate - employees	—	—	—	—	—	—	—	—
Training policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Fair remuneration policy	No	No	No	No	No	No	No	No
Number of employees – CSR	—	—	3,984	3,980	4,088	3,782	3,455	4,219
Employee turnover pct	—	—	—	—	—	7	7	8
Total hours spent by firm - employee training	—	—	247,805	268,252	283,707	207,353	195,380	234,480
Social supply chain management	No	No	No	No	No	Yes	Yes	Yes
Governance								
Board size	11	11	11	11	10	10	11	11
No. of independent directors (ID)	4	4	4	4	4	4	5	5
No. of women on board	3	3	3	3	3	3	3	3
No. of non-executive directors on board	8	8	9	9	9	9	10	10
Company conducts board evaluations	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
No. of board meetings for the year	5	4	6	4	4	7	4	4
Board meeting attendance pct	91	93	97	87	88	87	95	98
Board duration (years)	3	3	3	3	3	3	3	3
Director share ownership guidelines	No	No	No	No	No	No	No	No
Age of the youngest director	42	43	49	50	51	52	27	28
Age of the oldest director	75	75	78	79	79	80	78	79
No. of executives / company managers	7	6	6	6	4	4	4	5
No. of female executives	1	2	2	3	3	3	3	3
Executive share ownership guidelines	No	No	No	No	No	No	No	No
Size of audit committee	3	3	3	3	3	3	4	4
No. of ID on audit committee	3	3	3	3	3	3	4	4
Audit committee meetings	4	4	4	5	5	4	4	4
Audit meeting attendance %	100	92	92	87	100	100	87	100
Size of compensation committee	3	3	3	3	3	3	3	3
No. of ID on compensation committee	1	1	1	1	1	1	1	1
No. of compensation committee meetings	1	1	5	3	2	2	3	3
Compensation meeting attendance %	100	100	100	100	100	83	100	100
Size of nomination committee	3	3	3	3	3	3	3	3
No. of nomination committee meetings	1	1	5	3	2	2	3	3
Nomination meeting attendance %	100	100	100	100	100	83	100	100
Sustainability governance								
Verification type	No	No	No	No	No	No	No	No

Sources: Bloomberg; FSSIA's compilation

Disclaimer for ESG scoring

ESG score	Methodology	Rating																			
The Dow Jones Sustainability Indices (DJSI) By S&P Global	The DJSI World applies a transparent, rules-based component selection process based on the companies' Total Sustainability Scores resulting from the annual S&P Global Corporate Sustainability Assessment (CSA). Only the top-ranked companies within each industry are selected for inclusion.	Be a member and invited to the annual S&P Global Corporate Sustainability Assessment (CSA) for DJSI. Companies with an S&P Global ESG Score of less than 45% of the S&P Global ESG Score of the highest scoring company are disqualified. The constituents of the DJSI indices are selected from the Eligible Universe.																			
SET ESG Ratings List (SETESG) by The Stock Exchange of Thailand (SET)	SET ESG quantifies responsibility in Environmental and Social issues by managing business with transparency in Governance, updated annually. Candidates must pass the preemptive criteria, with two crucial conditions: 1) no irregular trading of the board members and executives; and 2) free float of >150 shareholders, and combined holding must be >15% of paid-up capital. Some key disqualifying criteria include: 1) CG score of below 70%; 2) independent directors and free float violation; 3) executives' wrongdoing related to CG, social & environmental impacts; 4) equity in negative territory; and 5) earnings in red for > 3 years in the last 5 years.	To be eligible for SETESG inclusion , verified data must be scored at a minimum of 50% for each indicator, unless the company is a part of DJSI during the assessment year. The scoring will be fairly weighted against the nature of the relevant industry and materiality. SETESG Index is extended from the SET ESG Ratings companies whose 1) market capitalization > THB5b (~USD150b); 2) free float >20%; and 3) liquidity >0.5% of paid-up capital for at least 9 out of 12 months. The SETTHSI Index is a market capitalisation-weighted index, cap 5% quarterly weight at maximum, and no cap for number of stocks.																			
CG Score by Thai Institute of Directors Association (Thai IOD)	An indicator of CG strength in sustainable development, measured annually by the Thai IOD, with support from the Stock Exchange of Thailand (SET). The results are from the perspective of a third party, not an evaluation of operations.	Scores are rated in six categories: 5 for Excellent (90-100), 4 for Very Good (80-89), 3 for Good (70-79), 2 for Fair (60-69), 1 for Pass (60-69), and not rated for scores below 50. Weightings include: 1) the rights; 2) and equitable treatment of shareholders (weight 25% combined); 3) the role of stakeholders (25%); 4) disclosure & transparency (15%); and 5) board responsibilities (35%).																			
AGM level By Thai Investors Association (TIA) with support from the SEC	It quantifies the extent to which shareholders' rights and equitable treatment are incorporated into business operations and information is transparent and sufficiently disclosed. All form important elements of two out of five the CG components to be evaluated annually. The assessment criteria cover AGM procedures before the meeting (45%), at the meeting date (45%), and after the meeting (10%). <i>(The first assesses 1) advance circulation of sufficient information for voting; and 2) facilitating how voting rights can be exercised. The second assesses 1) the ease of attending meetings; 2) transparency and verifiability; and 3) openness for Q&A. The third involves the meeting minutes that should contain discussion issues, resolutions and voting results.)</i>	The scores are classified into four categories: 5 for Excellent (100), 4 for Very Good (90-99), 3 for Fair (80-89), and not rated for scores below 79.																			
Thai CAC By Thai Private Sector Collective Action Against Corruption (CAC)	The core elements of the Checklist include corruption risk assessment, establishment of key controls, and the monitoring and developing of policies. The Certification is good for three years. <i>(Companies deciding to become a CAC certified member start by submitting a Declaration of Intent to kick off an 18-month deadline to submit the CAC Checklist for Certification, including risk assessment, in place of policy and control, training of managers and employees, establishment of whistleblowing channels, and communication of policies to all stakeholders.)</i>	The document will be reviewed by a committee of nine professionals. A passed Checklist will move for granting certification by the CAC Council approvals whose members are twelve highly respected individuals in professionalism and ethical achievements.																			
Morningstar Sustainabilitys	The Sustainabilitys' ESG risk rating provides an overall company score based on an assessment of how much of a company's exposure to ESG risk is unmanaged. <i>Sources to be reviewed include corporate publications and regulatory filings, news and other media, NGO reports/websites, multi-sector information, company feedback, ESG controversies, issuer feedback on draft ESG reports, and quality & peer reviews.</i>	A company's ESG risk rating score is the sum of unmanaged risk. The more risk is unmanaged, the higher ESG risk is scored. <table><tr><th>NEGL</th><th>Low</th><th>Medium</th><th>High</th><th>Severe</th></tr><tr><td>0-10</td><td>10-20</td><td>20-30</td><td>30-40</td><td>40+</td></tr></table>	NEGL	Low	Medium	High	Severe	0-10	10-20	20-30	30-40	40+									
NEGL	Low	Medium	High	Severe																	
0-10	10-20	20-30	30-40	40+																	
ESG Book	The ESG score identifies sustainable companies that are better positioned to outperform over the long term. The methodology considers the principle of financial materiality including information that significantly helps explain future risk-adjusted performance. Materiality is applied by over-weighting features with higher materiality and rebalancing these weights on a rolling quarterly basis.	The total ESG score is calculated as a weighted sum of the features scores using materiality-based weights. The score is scaled between 0 and 100 with higher scores indicating better performance.																			
MSCI	MSCI ESG ratings aim to measure a company's management of financially relevant ESG risks and opportunities. It uses a rules-based methodology to identify industry leaders and laggards according to their exposure to ESG risks and how well they manage those risks relative to peers. <table><tr><td>AAA</td><td>8.571-10.000</td><td rowspan="3">Leader:</td><td rowspan="3">leading its industry in managing the most significant ESG risks and opportunities</td></tr><tr><td>AA</td><td>7.143-8.570</td></tr><tr><td>A</td><td>5.714-7.142</td></tr><tr><td>BBB</td><td>4.286-5.713</td><td rowspan="3">Average:</td><td rowspan="3">a mixed or unexceptional track record of managing the most significant ESG risks and opportunities relative to industry peers</td></tr><tr><td>BB</td><td>2.857-4.285</td></tr><tr><td>B</td><td>1.429-2.856</td></tr><tr><td>CCC</td><td>0.000-1.428</td><td>Laggard:</td><td>lagging its industry based on its high exposure and failure to manage significant ESG risks</td></tr></table>	AAA	8.571-10.000	Leader:	leading its industry in managing the most significant ESG risks and opportunities	AA	7.143-8.570	A	5.714-7.142	BBB	4.286-5.713	Average:	a mixed or unexceptional track record of managing the most significant ESG risks and opportunities relative to industry peers	BB	2.857-4.285	B	1.429-2.856	CCC	0.000-1.428	Laggard:	lagging its industry based on its high exposure and failure to manage significant ESG risks
AAA	8.571-10.000	Leader:	leading its industry in managing the most significant ESG risks and opportunities																		
AA	7.143-8.570																				
A	5.714-7.142																				
BBB	4.286-5.713	Average:	a mixed or unexceptional track record of managing the most significant ESG risks and opportunities relative to industry peers																		
BB	2.857-4.285																				
B	1.429-2.856																				
CCC	0.000-1.428	Laggard:	lagging its industry based on its high exposure and failure to manage significant ESG risks																		
Moody's ESG solutions	Moody's assesses the degree to which companies take into account ESG objectives in the definition and implementation of their strategy policies. It believes that a company integrating ESG factors into its business model and relatively outperforming its peers is better positioned to mitigate risks and create sustainable value for shareholders over the medium to long term.																				
Refinitiv ESG rating	Designed to transparently and objectively measure a company's relative ESG performance, commitment and effectiveness across 10 main themes, based on publicly available and auditable data. The score ranges from 0 to 100 on relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly. <i>(Score ratings are 0 to 25 = poor; >25 to 50 = satisfactory; >50 to 75 = good; and >75 to 100 = excellent.)</i>																				
S&P Global	The S&P Global ESG Score is a relative score measuring a company's performance on and management of ESG risks, opportunities, and impacts compared to its peers within the same industry classification. The score ranges from 0 to 100.																				
Bloomberg	ESG Score	Bloomberg score evaluating the company's aggregated Environmental, Social and Governance (ESG) performance. The score is based on Bloomberg's view of ESG financial materiality. The score is a weighted generalized mean (power mean) of Pillar Scores, where the weights are determined by the pillar priority ranking. Values range from 0 to 10; 10 is the best.																			
Bloomberg	ESG Disclosure Score	Disclosure of a company's ESG used for Bloomberg ESG score. The score ranges from 0 for none to 100 for disclosure of every data point, measuring the amount of ESG data reported publicly, and not the performance on any data point.																			

[Rating](#) regarding the sustainable development of Thai listed companies, both on the SET and MAI, are publicly available on the website of the Securities and Exchange Commission of Thailand (SEC). Currently, ratings available are 1) "**CG Score**"; 2) "**AGM Level**"; 3) "**Thai CAC**"; and 4) **THSI**. The ratings are updated on an annual basis. FSSIA does not confirm nor certify the accuracy of such ratings.

Source: FSSIA's compilation

GENERAL DISCLAIMER

ANALYST(S) CERTIFICATION

Vatcharut Vacharawongsith FSS International Investment Advisory Securities Co., Ltd


The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Securities Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSSIA makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSSIA has no intention to solicit investors to buy or sell any security in this report. In addition, FSSIA does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

History of change in investment rating and/or target price

Bumrungrad Hospital (BH TB)



Date	Rating	Target price	Date	Rating	Target price	Date	Rating	Target price
22-Aug-2022	BUY	235.00	17-Aug-2023	BUY	300.00	24-Feb-2025	BUY	220.00
10-Nov-2022	BUY	255.00	05-Mar-2024	BUY	305.00	30-Jul-2025	HOLD	160.00
21-Feb-2023	BUY	260.00	03-May-2024	BUY	310.00			
09-May-2023	BUY	280.00	07-Nov-2024	HOLD	285.00			

Vatcharut Vacharawongsith started covering this stock from 30-Jul-2025

Price and TP are in local currency

Source: FSSIA estimates

Company	Ticker	Price	Rating	Valuation & Risks
Bumrungrad Hospital	BH TB	THB 178.50	HOLD	Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests or floods; 2) regulatory risks from drug prices and medical bill controls; and 3) higher medical fee discount promotions, leading to a weaker EBITDA margin.

Source: FSSIA estimates

Additional Disclosures

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited.

All share prices are as at market close on 04-Aug-2025 unless otherwise stated.

RECOMMENDATION STRUCTURE

Stock ratings

Stock ratings are based on absolute upside or downside, which we define as $(\text{target price}^* - \text{current price}) / \text{current price}$.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

Industry Recommendations

Overweight. The analyst expects the fundamental conditions of the sector to be positive over the next 12 months.

Neutral. The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months.

Underweight. The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

Country (Strategy) Recommendations

Overweight (O). Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Neutral (N). Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Underweight (U). Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.